CSIMarket Company Name, Ticker, Industry, else..
 
Forte Biosciences Inc   (NASDAQ: FBRX)
Other Ticker:  
 
 
Price: $6.7900 $0.95 16.267%
Day's High: $7.5726 Week Perf: 15.28 %
Day's Low: $ 6.75 30 Day Perf: 23.45 %
Volume (M): 14 52 Wk High: $ 28.00
Volume (M$): $ 94 52 Wk Avg: $11.67
Open: $7.47 52 Wk Low: $4.11



 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 3
 Employees 14
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -35
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 0

Forte Biosciences Inc
Forte Biosciences Inc is a biotechnology company that focuses on developing novel treatments for dermatological conditions. Their research and development efforts primarily revolve around harnessing the potential of the human microbiome to develop safe and effective therapeutic products. The company aims to address unmet needs in dermatology by developing microbiome-based treatments that can restore the balance of the skin microbiome and improve skin health. Forte Biosciences Inc is committed to advancing innovative solutions for various skin conditions and improving the quality of life for patients.


   Company Address: 3060 Pegasus Park Drive, Building 6 Dallas 75247 TX
   Company Phone Number: 618-6994   Stock Exchange / Ticker: NASDAQ FBRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.92%    
INVA        4.56% 
REGN   -3.26%    
TEVA        3.82% 
VRTX        3.97% 
VTRS        3.65% 
• View Complete Report
   



Business Update

Forte Biosciences Reports Positive Progress in Q2 2024; Advances FB102 Monoclonal Antibody Therapeutic Candidate

Published Thu, Aug 15 2024 5:37 AM UTC

Forte Biosciences, Inc., a clinical-stage biopharmaceutical company headquartered in Dallas, has announced significant developments in its operations during the second quarter of 2024, along with comprehensive financial results for the period. Since its inception, Forte has focused its efforts on addressing the unmet medical needs presented by autoimmune and autoimmune-relat...
Forte Biosciences Inc

Forte Biosciences Inc. Revolutionizes Major Pharmaceutical Preparations Market with Remarkable Third Quarter 2023 Earnings



Forte Biosciences, a biopharmaceutical company specializing in autoimmune and autoimmune-related diseases, recently released its financial results for the third quarter of 2023. The results revealed some unexpected challenges but also indicated potential opportunities for the company's future growth. This article discusses the implications of these financial results and their potential impact on Forte Biosciences' prospects going forward.
Operating Shortfall:
One of the key highlights from the financial report was Forte Biosciences' operating shortfall, which stood at $-10.216 million during the July to September 2023 reporting season. This represents a significant deterioration compared to the operating shortfall of $-3.423 million in the third quarter of 2022. The widening shortfall suggests that the company's expenses were outpacing its revenues, which could be a cause for concern among investors.
Forte Biosciences Inc

Strong Workouts and Growth Prospects Propel Forte Biosciences Inc. in Q2 2023

The Major Pharmaceutical Preparations industry is going through its reporting season for the period of April to June 30, 2023. During this time, numerous corporations have released their financial results. Among them is Forte Biosciences Inc. (FBRX), which reported an operating deficit of $-9.034 million for the second quarter of the earnings season.
Shareholders of Forte Biosciences Inc. are eagerly awaiting the announcement of additional business strategies in the near future. This indicates that they are more focused on the potential growth and future plans of the company rather than its current organizational and operational performance.
Forte Biosciences Inc

Forte Biosciences Inc (FBRX) Fights for Survival Amidst Challenging Market Conditions with $6.855 Million Operating Loss in Q1 2023

In the world of pharmaceutical preparations, the big players always steal the limelight. But what about the lesser-known corporations that are trying to make a dent in the market? Well, it appears that some of them are struggling to stay afloat.
Forte Biosciences Inc (FBRX) recently reported an operating loss of $-6.855 million for the first quarter of 2023. This is a significant deterioration from the first quarter of 2022, when the operating loss was $-2.514 million. This news has raised questions about when the major pharmaceutical preparations companies will start to show revenue.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com